Iloprost
Drugs Market, By Route of Administration (Intravenous, and Inhalation), By
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019
- 2027
Iloprost is a drug used for
treating diseases such as pulmonary arterial hypertension, scleroderma, Raynaud
syndrome, and other conditions where constriction in blood vessels and improper
blood flow in tissues is found. The trade name of the drug is Ventavis or
Ilomedine. Iloprost, which received approval by the U.S. Food and Drug
Administration (FDA) in 2004 for pulmonary arterial hypertension.
Iloprost dilates the narrowed
blood vessels (arteries) in lungs which results in decreased pulmonary blood
pressure to the heart. The drug can be administered either through infusion or
it can be inhaled using nebulizers. The infusion is administered intravenously
which lasts for about six hours in a day and the session is repeated for three
to five days in a row whereas the inhalations should be done six to nine times
in a day, according to the physician’s prescription.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3284
Global Iloprost Drugs Market –
Dynamics
Increasing prevalence of
pulmonary arterial hypertension is expected to propel the market growth over
the forecast period. For instance, according to the National Organization for
Rare Disorder (NORD), 2018, nearly 500 to 1000 new cases of pulmonary arterial
hypertension are diagnosed each year in the U.S.
Moreover, various merges,
agreements and acquisitions of major companies are likely to propel the market
growth. For instance, in January 2017, Acetlion announced that Johnson &
Johnson will be acquiring the firm including its marketed products in pulmonary
arterial hypertension franchise.
Furthermore, increasing number of
players are focusing on developing this drug, in order to, which is also
contributing to the market growth over the forecast period. For instance, in
2018, according to the National Institute of Health, approximately15 clinical
trials involving Iloprost were active globally. For instance, in November 2015,
the National Cancer Institute initiated a phase I clinical trial for evaluating
iloprost in preventing recurrence of lung cancer for patients who smoke and the
study is expected to complete in 2020.
However, the drug has some side
effects such as kidney failure, dyspnea, chest pain, short breath, and swelling
of limbs. The above stated side effects are expected to restrain the market growth
over the forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/iloprost-drugs-market-3284
Global Iloprost Drugs Market –
Regional insights
North America accounted for the
largest market share in 2018, owing to mergers, agreements, and acquisitions by
key players in the region. For instance, in August 2019, VisionGate, a U.S.
-based oncology pharmaceutical and diagnostics company, received an exclusive
worldwide right and license from Bayer AG for the technology to develop,
manufacture, sale, and commercialize iloprost betadex clathrate in the field of
lung cancer treatment and prevention. Also, in 2012, Bayer AG collaborated with
Vectura to develop Breelib, which is a hand held nebulizer device designed for
improved delivery of Bayer’s Ventavis (iloprost).
Global Iloprost Drugs Market -
Competitive Landscape
Key manufactures in the market
include Actelion Pharmaceuticals, Bayer AG, Vectura Group Plc., and VisionGate.
Moreover, key players in market are focused on developing new products, in
order to enhance their market share. For instance, in 2017, Bayer AG and
Vectura Group Plc. extended their collaboration again to develop an upgraded
version of nebulizer Breelib which improves the efficacy of iloprost aerosol
therapy in pulmonary atrial hypertension. According to the National Institute
of Health, the nebulizer is still in clinical trial and the study is expected
to finish in March 2020.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3284
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment